| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
There is a disruption in the p53 pathway in almost all human tumors. SJ-172550 displaces p53 via attaching to the p53 binding pocket of MDMX. MDMX is reversibly bound by SJ-172550, which also efficiently kills retinoblastoma cells that have elevated MDMX expression. When SJ-172550 is used with the MDM2 inhibitor nutlin-3a, the effects are cumulative [1]. SJ-172550 functions by locking MDMX into a conformation that prevents it from binding p53 through the development of a covalent but reversible complex with the chemical. Numerous elements influence this complex's relative stability, such as the medium's capacity for reduction and the existence of aggregates [2].
|
|---|---|
| References |
| Molecular Formula |
C22H21CLN2O5
|
|---|---|
| Molecular Weight |
428.869
|
| Exact Mass |
428.113
|
| Elemental Analysis |
C, 61.61; H, 4.94; Cl, 8.27; N, 6.53; O, 18.65
|
| CAS # |
431979-47-4
|
| PubChem CID |
2913564
|
| Appearance |
Pink to red solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
560.8±60.0 °C at 760 mmHg
|
| Flash Point |
293.0±32.9 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.586
|
| LogP |
3.73
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
30
|
| Complexity |
689
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C(=C(C([H])=C(C=1[H])/C(/[H])=C1/C(N(C2C([H])=C([H])C([H])=C([H])C=2[H])N=C/1C([H])([H])[H])=O)OC([H])([H])C([H])([H])[H])OC([H])([H])C(=O)OC([H])([H])[H]
|
| InChi Key |
RKKFQJXGAQWHBZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H21ClN2O5/c1-4-29-19-12-15(11-18(23)21(19)30-13-20(26)28-3)10-17-14(2)24-25(22(17)27)16-8-6-5-7-9-16/h5-12H,4,13H2,1-3H3
|
| Chemical Name |
methyl 2-[2-chloro-6-ethoxy-4-[(3-methyl-5-oxo-1-phenylpyrazol-4-ylidene)methyl]phenoxy]acetate
|
| Synonyms |
SJ172550. MDMX Inhibitor II; SJ 172550; SJ-172550
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~77.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3317 mL | 11.6585 mL | 23.3171 mL | |
| 5 mM | 0.4663 mL | 2.3317 mL | 4.6634 mL | |
| 10 mM | 0.2332 mL | 1.1659 mL | 2.3317 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
